Ariel Ekblaw

That is what they did towards the end of the ISS.

We had ISS National Lab, ISSNL.

It did happen.

And that enabled my PhD, because as a student, I was able to get basically subsidized support to fly my little self-assembling prototypes via ISS National Lab.

Now I think we're 10, 15 years after that, now we are ready for commercial space.

And so what NASA is going to do to replace the International Space Station is truly commercial modules where these companies like Axiom are getting hundreds of millions of dollars in VC investment.

People out there really do believe they can make money off of not just biotech, but also ball bearings.

This would be their tube.

They're going to go back to a pressure cylinder.

We want our buckyball to be an appendage on the Axiom Space Station or the Voyager Star Lab or the VAST Space Station.

So we will be kind of next-gen habitat tech that gets tested out in the next five years on the attachment side of a more traditional space station that's going to replace the International Space Station.

Benefiting who's them?

That's the trick.

It's actually better than just it being science fiction, like going to die on Mars.

It's about infrastructure on Earth and where are they selling?

It's Earth-based markets.

It has to come back down and be of pragmatic use to someone on Earth for it to make sense.

So I think that there's a nuance there.

It can benefit life on Earth.

It is.